The second-quarter 2026 reporting cycle of the Medical sector is currently in full swing. The sector mainly comprises pharma/biotech and medical device companies.With many pharma and biotech bigwigs having already reported results, the earnings picture has been encouraging. Nearly all of these comp…
As per a media report over the weekend, AstraZeneca Plc (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) are in potential discussions to form a pharmaceutical giant valued at nearly $400 billion.The news took the healthcare sector by storm, and the merger would position AstraZeneca as the world’s…
Global pharmaceutical company Pfizer NYSE:PFEwill be reporting earnings this Tuesday before market hours. Here’s what to expect.Pfizer beat analysts’ revenue expectations last quarter, reporting revenues of $14.45 billion, up 5.4% year on year. It was a mixed quarter for the company, with a beat of…
Shares of Sellas Life Sciences (SLS) are sliding toward their worst month in over two years, but retail bulls are still buying weakness and holding out for a potential buyout as the company nears a key acute myeloid leukemia (AML) readout.SLS stock SLS stock has fallen 31% so far in July after exte…
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen…
Shares of Sellas Life Sciences (SLS) jumped 3% overnight late Monday as retail traders bet that the final acute myeloid leukemia (AML) readout could turn this week’s Fox appearance into a launchpad for Big Pharma interest.SLS stock surged 12% on Friday to close at $13.19, capping a 3% weekly gain.S…
Pfizer Price Target Maintained With a $27.00/Share by Cantor Fitzgerald
Pfizer Inc. (NYSE:PFE) reported stronger‑than‑expected Q1 revenue but missed full‑year EPS guidance, sending the stock down about 8.5% to near $24.08, while the company faces a U.S. House probe into China trials and a judge ordered faster FDA release of COVID‑vaccine approval documents.Previous Wee…
(10:04 GMT) Pfizer Price Target Cut to $28.00/Share From $32.00 by HSBC
